Navigation Links
Fox Chase finds all-biologic regimen efficacious and well-tolerated in elderly lung cancer patients
Date:8/1/2009

SAN FRANCISCO (August 1, 2009)Previously untreated non-small cell lung cancer (NSCLC) patients over the age of 70 respond well to a combination of bevacizumab and erlotinib, Fox Chase Cancer Center researchers reported today at the annual meeting of the International Association for the Study of Lung Cancer.

"Based on our initial data, the combination appears to be well tolerated and efficacious, though we'll have to wait and see the final results," says Hossein Borghaei, D.O., medical oncologist at Fox Chase, who led the trial.

Elderly patients are often excluded from clinical trials because researchers fear they will have trouble tolerating standard chemotherapy regimens. That leaves open the question of how best to treat these individuals who account for more than half of all NSCLC in the United States.

With that challenge in mind, Borghaei and colleagues designed a trial testing a combination of two molecularly targeted agents in patients 70 years or older. The team reasoned that a combination lacking standard cytotoxic agents may be better tolerated by these patients, potentially without comprising efficacy. "We looked for a regimen that had few side effects, would involve only targeted agents, and had a bit of a track record. This combination was a natural fit," Borghaei says. Several small phase II trials in younger NSCLC patients demonstrated that the combination had anti-tumor activity and a relatively favorable toxicity profile.

Thus far 21 elderly NSCLC patients have enrolled in the Fox Chase trial and 14 are evaluable for response. The median age of the 14 evaluable patients is 78, with a range of 71 to 84 years. Four patients have had partial responses with demonstrable tumor shrinkage and three patients had stable disease by RECIST criteria.

The combination appears safe and well tolerated in this patient population with the most commonly encountered toxicities of clinical relevance being high blood pressure, fatigue, loss of appetite and diarrhea.

"The observed activity of this regimen in this patient population suggests promise and therefore warrants continued investigation," Borghaei says. He also emphasizes that designing a clinical trial just for elderly patients is a novel approach, but one that should be used more in the future given the large proportion of NSCLC patients in this demographic group.


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. MaxLife Fund Corp. purchases a portfolio of Life Settlement Policies with a face value of $4,000,000
2. Northstar Healthcare Announces Option to Purchase a 60% Interest in The Palladium for Surgery - Dallas
3. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
4. Consumer Group: Hillary Clintons Mandatory Health Insurance Purchase Plan is an Act of War on the Middle Class Family That Cant Afford $12k Policy
5. Kensey Nash Announces $25 Million Stock Repurchase Program
6. Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance
7. Flextronics Announces Redemption and Change of Control Repurchase Offer for Solectron 8.00% Senior Subordinated Notes and Planned Change of Control Repurchase Offer for Solectrons 0.50% Senior Convertible Notes
8. First Nationwide Class Action Filed on Behalf of Consumers Who Purchased Topps E. Coli Contaminated Ground Beef
9. Hospital Corporation of America Purchases Seventh CyberKnife(R) System
10. Dixtal Medical Purchases Novametrix Pulse Oximetry Business from Respironics
11. Governor Schwarzeneggers Mandatory Purchase of Private Health Insurance Doesnt Add Up for the Middle-Class, Says FTCR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Dallas, TX (PRWEB) , ... December 07, 2016 ... ... service based in Dallas, Texas, is condemning "scam operations" carried out by unethical ... to bring these scam operations to a halt. According to Texas Premier Locksmith, ...
(Date:12/7/2016)... Aliso Viejo, California (PRWEB) , ... December 07, 2016 , ... ... placed above any and all media," said Christina Austin - CEO of Pixel Film ... of logo with easy to use drop zones. Editors can select from a variety ...
(Date:12/7/2016)... ... 2016 , ... Maureen McLaughlin, LA.c., a certified acupuncturist, is ... Connecticut (RMACT). McLaughlin brings nearly 20 years of experience with fertility patients to ... their family building goals. Acupuncture helps fertility patients by supporting the ...
(Date:12/7/2016)... , ... December 07, 2016 , ... “Walking With God: ... stories that will inspire the reader to be aware of God's direction in their ... published author, Sanford Smith, retired teacher and active church leader. , Sanford ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Business Architecture Guild ... Reston, VA on March 21-22, 2017. This premier event features business practitioners and ... a cross-section of industries such as financial services, insurance, healthcare, manufacturing, transportation, retail, ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... 2016  "Blood Tests replace Surgical Biopsies. Single ... The Diagnostic, Monitoring and Screening Test opportunities are ... occurring using in vitro blood testing to identify ... backing, has announced a single blood test to ... than the market. New technology that definitively identifies ...
(Date:12/6/2016)... Anaplastic Oligoastrocytoma - Pipeline Review, H2 ... Pharmaceutical and Healthcare disease pipeline guide Anaplastic Oligoastrocytoma ... of the Anaplastic Oligoastrocytoma (Oncology) pipeline landscape. ... when two types of cells in the brain, ... to form a mass. These brain cells are ...
(Date:12/6/2016)... LOUISVILLE, Ky. , Dec. 6, 2016 /PRNewswire/ ... notice of accreditation from the College of American ... Improvement Amendments (CLIA) for its new laboratory in ... company recently moved its North American headquarters. ... offers Sanger sequencing -- which is still considered ...
Breaking Medicine Technology: